Can IPT be carried out on an outpatient basis?

Yes, IPT can be done on an outpatient basis because it has little to no side effects and does not burden the patient physically or mentally.

IPT should cause little to no side effects. What side effects can still exist?

Thanks to the low-dose of chemotherapy and medical drugs, patients usually do not feel side effects. However, it sometimes happens during therapy that the patient sweats intensely, feels a bit lethargic, or may have a tightness in their chest. However, all of these phenomena start to disappear after the therapy session.

Should the attending physician be a certified IPT user?

Even if the therapy is easy to perform, per se, the attending physician must possess extensive specialist knowledge, which in this form can only be obtained through Dr. med. Donato Perez Garci­a III, the grandson of the founder of the therapy, and his employees. This credible training does not only consist of a one-time basic education, but is constantly being updated and supplemented by advanced training courses.

Why is IPT not recognized as a conventional medicine in Europe?

IPT comes from applied medicine, meaning it was developed by general practitioners and constantly refined throughout the decades. By now, many tens of thousands of patients have been treated with IPT, but unlike the procedures that are being developed by the industry with millions of dollars in funding, it can not boast with a host of expensive, industry-standard clinical trials. Let us remember, however, for example, that homeopathy and many other procedures that are universally known and practiced successfully, are not recognized as conventional medicine, solely because they do not seem to meet industry’s standards. Many independent institutions, however, for example the Gesellschaft für biologische Krebsabwehr e. V. (Society for Biological Cancer Defense) in Heidelberg, strongly recommend IPT.

What cost does the patient have to expect?

The cost of treatment can only be calculated after an anamnesis and taking into account individual parameters and the indication. The patient will receives a binding cost statement from the treating physician before any treatment.

Are there scientific studies demonstrating the effectiveness of IPT?

Insulin Potentation Therapy is not a product of research industry laboratories, but arose from experience, meaning it was developed by practicing physicians and refined over the decades. Accordingly, IPT – like so many other sensible forms of therapy that do not receive funding from the industry – barley had any of the millions of dollars available, which are necessary to publish numerous large-scale studies in accordance with today’s standards. The following statements and contents on other pages of this website are supported by studies, which are referred to below. The last study listed (University of Montevideo) was performed on patients (breast cancer) and meets scientific standards.

Studies on IPT

Insulin, which activates and modifies metabolic pathways in MCF-7 human breast cancer cells, is shown to increase the cytotoxic effect of methotrexate up to ten thousand-fold in vitro.

Metabolic Modification by Insulin Enhances Methotrexate Cytotoxicity in MCF-7 Human Breast Cancer Cells – Alabaster O, Vonderhaar BK, Shafie SM. Eur J Cancer Clin Oncol 17:1223-1228, 1981 Georg Washington Universität (1981).

Human breast cancer cells have six times more insulin (1) and ten times more IGF-I receptors (2) than normal tissue in the body. (IGF = Insulin-like Growth Factor).

Hormone binding by human mammary carcinoma - Holdaway IM, Freisen HG. Cancer Res 37:1946-1952, 1977 and IGF-I receptor expression and function in HBCC - Cullen JK et al. Cancer Res, 50:48-53, 1990.

A reversible metabolic promoter, insulin enhances the cytotoxity of the chemotherapeutic agents. It is possible to increase the growth and metabolism of cancer cells first so as to enhance the chemosensibility, and then administer chemotherapeutic agents, thus improving their therapeutic effects.

Zhonghua Yi Xue Za Zhi. 2003 Feb 10;83(3):195-7. Article in Chinese, PMID: 12812659 Abstract from PubMed.

The secretion of insulin and IGF-1 and the production of specific receptors for insulin in populations of human breast cancer cells have been well demonstrated by the following authors:

Hormone binding by human mammary carcinoma – Holdaway I.M., Freisen H.G. Cancer Res 37:1946-1952, 1977. Insulin-like growth factor receptor expression and function in human breast cancer – Cullen J.K., Yee D., Sly W.S., et al. . Cancer Res 50:48-53, 1990. Elevated insulin receptor content in human breast cancer - Papa V., Pezzino V., Costantino A., et al. J Clin Invest 86:1503-1510, 1990.

In multidrug-resistant metastatic breast cancer, methotrexate insulin produced a significant antitumoral response that was not seen with either methotrexate or insulin used separately. Our results confirmed in vivo the results of previous in vitro studies showing clinical evidence that insulin potentiates methotrexate under conditions where insulin alone does not promote an increase in tumor growth. Therefore, the chemotherapy antitumoral activity must have been enhanced by the biochemical events elicited in tumor cells by insulin.

Insulin-induced Enhancement of Antitumoral Response to Methotrexate in Breast Cancer Patients – Lasalvia-Prisco E,Cucchi S, Vazquez J, Lasalvia-Galante E, Golomar W, Gordon W., Cancer Chemotherapy and Pharmacology, 2003, 10.1001/s00280-0030716-7.

Supraphysiological concentrations of insulin can replace the IGF-I requirement in a defined medium, namely by a cross-reaction with the IGF-I receptor.

Growth factors and cancer – Goustin et al. Cancer Res 46:1015-1029, 1986.

We are suggesting that malignant transformation of cells may result from inappropiate later expression of autocrine growth factors that were required by cells during normal early embryogenesis. The recent isolation and characterization of defined polypetide transforming growth factors, which apear to function by such autocrine mechanisms, suggest that malignant transformation may be controlled some time in the future by means of specific inhibitors of the action of these peptides.

Autocrine secretion and malignant transformation of cells – Sporn MB, Todaro GJ. NEJM, 308:487-490, 1980

This combination of insulin and IGF-I acts autonomously at the cellular level within tumors, independently from any integrated higher-level control. These two work together in an autocrine and/or a paracrine as well as a complementary way, with IGF-I being the more important anabolic hormone responsible for communicating information regarding growth in the tumor, whereas insulin provides and regulates the energy required for these processes.

Insulin-like growth factors/somatomedins: structure, secretion, biological actions and physiological role – Zapf J., Froesch E.R. . Hormone Res 24:121-130, 1986.

After insulin was added to the asynchronous population of breast cancer cells, the S-phase split was 66% in vitro, compared to only 37% in the control.

Perturbation by insulin of human breast cancer cell kinetics – Gross GE, Boldt DH, Osborne CK . Cancer Res 44:3570-3575, 1984.

The dream of eternal youth and health is as old as humanity itself.

Private practice Martin LeeGeneral and holistic medicine / Argelander Str. 173 / 53115 Bonn (Germany) / E-Mail: / T (0)228 91800060